Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.05Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 31, 2025
|% Change Since: -34.45%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant regulatory and strategic advancements, cost reduction measures, and commitment from the leadership team. However, it also acknowledged delays in the Phase 3b trial initiation, financial constraints, and skepticism about NurOwn's efficacy. The company is focused on overcoming these challenges with strategic funding and partnerships.Company Guidance
In the recent earnings call, BrainStorm Cell Therapeutics provided detailed guidance on their strategic focus and financial outlook for 2025. The company is prioritizing the execution of the critical Phase 3b trial of NurOwn, their investigational treatment for ALS, with the aim of confirming its potential to significantly slow disease progression in early-stage patients. They have secured a special protocol assessment from the FDA, which derisks the regulatory pathway, and are in active negotiations with approximately 15 leading clinical centers in the U.S. to finalize clinical trial agreements. The company anticipates that they will need approximately $20 million to $30 million annually to fund the trial, and they are actively pursuing multiple funding avenues, including licensing non-core assets and exploring non-dilutive financing opportunities. Additionally, BrainStorm has partnered with IQVIA for trial execution and has contracted with Pluri Inc. for clinical manufacturing. As of December 2024, the company's cash, cash equivalents, and restricted cash stood at approximately $0.4 million, compared to $1.5 million at the end of 2023, and they have announced a warrant inducement agreement expected to raise approximately $1.64 million in gross proceeds.Regulatory Advancements
Secured a special protocol assessment with the FDA, significantly derisking the regulatory pathway for NurOwn, the ALS treatment.
Strategic Partnerships for Trial Execution
Partnership with IQVIA for managing the Phase 3b trial and with Pluri Inc. for GMP compliant production of NurOwn.
Cost Reduction Achievements
Research and development expenses reduced from $10.7 million in 2023 to $4.7 million in 2024. General and administrative expenses also decreased from $10.7 million in 2023 to $7 million in 2024.
Financial Strategy and Inducement
Raised approximately $1.64 million through a warrant inducement agreement. Actively pursuing multiple funding avenues including licensing non-core assets and exploring non-dilutive financing opportunities.
Commitment from Leadership
Senior leadership and staff have taken salary reductions or worked without compensation to advance the trial.
---
BCLI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BCLI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 31, 2025 | $1.19 | $1.26 | +5.88% |
| Nov 14, 2024 | $1.13 | $1.21 | +7.08% |
| Aug 14, 2024 | $4.78 | $4.58 | -4.18% |
| May 14, 2024 | $7.50 | $7.26 | -3.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Brainstorm Cell Therapeutics (BCLI) report earnings?
Brainstorm Cell Therapeutics (BCLI) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Brainstorm Cell Therapeutics (BCLI) earnings time?
Brainstorm Cell Therapeutics (BCLI) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BCLI EPS forecast?
BCLI EPS forecast for the fiscal quarter 2025 (Q1) is -0.38.
---